Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Integra LifeSciences Holdings Corporation is a medical devices business based in the US. Integra LifeSciences Holdings Corporation shares (IART) are listed on the NASDAQ and all prices are listed in US Dollars. Integra LifeSciences Holdings Corporation employs 4,000 staff and has a trailing 12-month revenue of around USD$1.4 billion.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$65.87 |
---|---|
52-week range | USD$34.21 - USD$66.57 |
50-day moving average | USD$57.1327 |
200-day moving average | USD$49.9843 |
Wall St. target price | USD$60.33 |
PE ratio | 100.5909 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.66 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $65.87 from 2021-01-11
1 week (2021-01-07) | 0.05% |
---|---|
1 month (2020-12-15) | 10.50% |
3 months (2020-10-15) | 37.37% |
6 months (2020-07-15) | 31.69% |
1 year (2020-01-15) | 12.95% |
---|---|
2 years (2019-01-15) | 43.60% |
3 years (2018-01-13) | N/A |
5 years (2016-01-15) | 4.79% |
Valuing Integra LifeSciences Holdings Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integra LifeSciences Holdings Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integra LifeSciences Holdings Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 101x. In other words, Integra LifeSciences Holdings Corporation shares trade at around 101x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Integra LifeSciences Holdings Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9183. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integra LifeSciences Holdings Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Integra LifeSciences Holdings Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$324 million.
The EBITDA is a measure of a Integra LifeSciences Holdings Corporation's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$1.4 billion |
---|---|
Operating margin TTM | 14.97% |
Gross profit TTM | USD$978.1 million |
Return on assets TTM | 3.79% |
Return on equity TTM | 4.06% |
Profit margin | 4.1% |
Book value | $16.588 |
Market capitalisation | USD$5.6 billion |
TTM: trailing 12 months
There are currently 3.4 million Integra LifeSciences Holdings Corporation shares held short by investors – that's known as Integra LifeSciences Holdings Corporation's "short interest". This figure is 6% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Integra LifeSciences Holdings Corporation shares can be evaluated.
Integra LifeSciences Holdings Corporation's "short interest ratio" (SIR) is the quantity of Integra LifeSciences Holdings Corporation shares currently shorted divided by the average quantity of Integra LifeSciences Holdings Corporation shares traded daily (recently around 377660.15538291). Integra LifeSciences Holdings Corporation's SIR currently stands at 9.01. In other words for every 100,000 Integra LifeSciences Holdings Corporation shares traded daily on the market, roughly 9010 shares are currently held short.
However Integra LifeSciences Holdings Corporation's short interest can also be evaluated against the total number of Integra LifeSciences Holdings Corporation shares, or, against the total number of tradable Integra LifeSciences Holdings Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Integra LifeSciences Holdings Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Integra LifeSciences Holdings Corporation shares in existence, roughly 40 shares are currently held short) or 0.0554% of the tradable shares (for every 100,000 tradable Integra LifeSciences Holdings Corporation shares, roughly 55 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Integra LifeSciences Holdings Corporation.
Find out more about how you can short Integra LifeSciences Holdings Corporation stock.
We're not expecting Integra LifeSciences Holdings Corporation to pay a dividend over the next 12 months.
Integra LifeSciences Holdings Corporation's shares were split on a 2:1 basis on 4 January 2017. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Integra LifeSciences Holdings Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Integra LifeSciences Holdings Corporation shares which in turn could have impacted Integra LifeSciences Holdings Corporation's share price.
Over the last 12 months, Integra LifeSciences Holdings Corporation's shares have ranged in value from as little as $34.21 up to $66.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Integra LifeSciences Holdings Corporation's is 1.2005. This would suggest that Integra LifeSciences Holdings Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it sells hardware products, such as bone and joint fixation, and joint replacement devices; and implants and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was founded in 1989 and is headquartered in Princeton, New Jersey.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.